Cooperative Agreement HT94252520004
Award Date
8/1/25
Completion Date
7/31/29
Dollars Obligated
$5.7M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Cooperative Agreement
Place of Performance
Nashville, TN 37232, USA
Similar Awards
This Cooperative Agreement award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,400,000.00 to Vanderbilt University Medical Center (VUMC) to support the Kidney Cancer Clinical Trials Consortium. The award commenced on September 15, 2024 and will run through September 14, 2028. Through this funding, VUMC will conduct advanced biomedical research and clinical trials focused on transforming healthcare for military service...
This federal Project Grant award of $1,267,303.00 from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to Vanderbilt University Medical Center supports research to define chronic immune-related adverse events in melanoma survivors. The award period runs from August 1, 2025 to July 31, 2028. The Military Medical Research and Development program funds advanced biomedical research to transform healthcare for military service members, veterans, and the public,...
The U.S. Department of Defense's Defense Health Agency awarded a $1,317,028 Project Grant to Vanderbilt University Medical Center (VUMC) with a period of performance from June 1, 2024 to May 31, 2028. The grant, under CFDA 12.420 - Military Medical Research and Development program, will support VUMC's research into therapeutic interventions to reverse gastric precancer. As a leading academic medical center and biomedical research institution, VUMC will leverage its clinical expertise and...
The Department of the Army Medical Command awarded Vanderbilt University Medical Center (VUMC) a $1,310,914 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on monitoring peripheral immunity to chemotherapy and immunotherapy in breast cancer. The 3-year award, which began on February 1, 2024, aims to advance the understanding of biomarkers and identify novel therapies for breast cancer treatment. As a leading academic medical center with...
This federal Project Grant award of $2,399,874.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research by Vanderbilt University Medical Center (VUMC) to investigate the molecular basis of post-injury syndromes and mineralization disorders. The research aims to transform healthcare for military service members, veterans, and the broader public. The 4-year award, which commenced on August 1, 2025, will fund a diverse...
This $1,211,469 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports a therapeutic intervention research project to reverse gastric precancer conducted by Vanderbilt University Medical Center (VUMC). The award, with a performance period from June 1, 2024 to May 31, 2028, will enable VUMC to leverage its clinical expertise and research capabilities to advance medical knowledge and improve patient care. As a leading...
This Cooperative Agreement award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $19,100,256 to The University of Texas MD Anderson Cancer Center in Houston, TX over a 4-year period from August 1, 2025 to July 31, 2029. The purpose of the award is to support the "CONVERGENT SCIENCE CANCER CONSORTIUM FOR IMMUNE CELL ENGINEERING" which aims to advance biomedical research and transform healthcare for military service...
This $1,432,794 federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a research project at Vanderbilt University Medical Center (VUMC) titled "Gene Expression Analysis of Circulating Tumor Cells: A Next-Generation Biomarker to Predict Immunotherapy Response in Metastatic Clear Cell Renal Cell Carcinoma". The 4-year project, with a start date of September 15, 2024 and end date of September...
This federal Cooperative Agreement award in the amount of $1,242,250.00 was granted by the Defense Health Agency to Duke University on September 15, 2024 under the Military Medical Research and Development (CFDA 12.420) program. The award supports the Kidney Cancer Research Program Clinical Consortium, providing funding for a Duke University clinical trial site. This award extends and adds funding to an existing project, with a new ultimate completion date of September 14, 2028. The Military...
The Department of the Army Medical Command awarded a $782,955.27 Project Grant to Vanderbilt University Medical Center on September 15, 2022, with a completion date of September 14, 2025. The grant supports research under the Military Medical Research and Development program (CFDA 12.420) to modulate lung and bone microenvironments to treat breast cancer metastases. The program aims to transform military and public health through innovative biomedical research solutions for battlefield...